LEVOSIMENDAN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H12N6O
Molecular Weight	280.2847
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2

InChI

InChIKey=WHXMKTBCFHIYNQ-SECBINFHSA-N

InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H12N6O
Molecular Weight	280.2847
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28262914 | http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=30004 |

Levosimendan (Simdax) is a novel intravenous agent that exerts inotropic effects through sensitization of myofilaments to calcium and vasodilator effects by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. Unlike other calcium sensitizing compounds, the binding of levosimendan is highly dependent on the intracellular concentration of calcium, such that calcium sensitivity is enhanced only when the calcium level is elevated. Levosimendan is licensed for the treatment of decompensated heart failure in many countries but not in North America. This drug also passed phase III clinical trials for the prevention of low cardiac output syndrome in pediatric patients after open heart surgery.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Troponin C, slow skeletal and cardiac muscles 1 Target ID: P63316 Gene ID: 7134.0 Gene Symbol: TNNC1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21784540	Binding Agent 1076
ATP-sensitive inward rectifier potassium channel 11 10 Target ID: Q14654 Gene ID: 3767.0 Gene Symbol: KCNJ11 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17452812	Opener 34
ATP-sensitive inward rectifier potassium channel 8 9 Target ID: Q15842 Gene ID: 3764.0 Gene Symbol: KCNJ8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17452812	Opener 34

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute heart failure 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15038409	Primary		Approved 8583	Simdax Approved Use Unknown
Low cardiac output syndrome 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28262914	Preventing		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
256.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27122803/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
15.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
17.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
16.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
17.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
207.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27122803/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2510 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5970 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1650 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3950 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2370 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3890 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
91 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
57 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
56 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
56 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
40 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
113 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
120 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
47 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 1 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
126 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 3 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
65 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
128 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342615/	2 mg 4 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27122803/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
72.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
78.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
81.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
81.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.1 μg/kg/min 1 times / week steady-state, intravenous dose: 0.1 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
0.85% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27122803/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	LEVOSIMENDAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
58% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1855 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
61% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15025738/	0.05 μg/kg/min 1 times / week steady-state, intravenous dose: 0.05 μg/kg/min route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OR-1896 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
4 mg 1 times / day multiple, intravenous Highest studied dose Dose: 4 mg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8907133/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8907133/	Sources: https://pubmed.ncbi.nlm.nih.gov/8907133/
5 mg single, intravenous Highest studied dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7867680/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7867680/	Sources: https://pubmed.ncbi.nlm.nih.gov/7867680/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252		inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP19A1 429 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 25.0	inconclusive [IC50 13.8029 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 95.0	inconclusive
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 170.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 166.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 3.0	yes [IC50 0.9772 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 31.0	yes [IC50 17.3768 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/3033825#section=BioAssay-Results Page: 11.0

PubMed

Title	Date	PubMed
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.	2007-05-02	17473298
A review of levosimendan in the treatment of heart failure.	2006	17323593

Patents

Sample Use Guides

In Vivo Use Guide

0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.

Route of Administration: Intravenous

In Vitro Use Guide

Levosimendan down-regulates the expression of the pro-thrombotic and anti-fibrinolytic biomolecules TF and PAI-1 in activated human endothelial cells. Human heart microvascular endothelial cells (HHMEC) and human umbilical vein endothelial cells (HUVEC) were treated with interleukin-1β (IL-1β) (200U/mL) or thrombin (5U/mL) and co-treated with or without levosimendan (0.1-10μM) for 2-24h. In addition, flow experiments were performed. Effects on plasminogen activator inhibitor-1 (PAI-1) and tissue factor (TF) expression and activity were measured by rt-PCR, specific ELISA and flow cytometry.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:17 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:17 GMT 2025`
Record UNII	C6T4514L4E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOSIMENDAN

Official Name

English

SIMDAX

Preferred Name

English

(-)-OR-1259

Code

English

PROPANEDINITRILE, 2-(2-(4-((4R)-1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZINYLIDENE)-

Systematic Name

English

LEVOSIMENDAN [USAN]

Common Name

English

LEVOSIMENDAN [MART.]

Common Name

English

2-(2-(4-((4R)-1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZINYLIDENE)PROPANEDINITRILE

Systematic Name

English

PROPANEDINITRILE, ((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZONO)-, (R)-

Common Name

English

levosimendan [INN]

Common Name

English

MESOXALONITRILE (P-((R)-1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-PYRIDAZINYL)PHENYL)HYDRAZONE

Common Name

English

(R)-SIMENDAN

Common Name

English

SIMENDAN, (R)-

Common Name

English

LEVOSIMENDAN [MI]

Common Name

English

OR1259

Code

English

OR-1259

Code

English

(R)-((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZONO) PROPANEDINTRILE

Common Name

English

Levosimendan [WHO-DD]

Common Name

English

NSC-759644

Code

English

Classification Tree Code System Code

WHO-ATC

C01CX08